tetano
Editor, Senior Moderator
Ann Hematol
. 2023 Dec 14.
doi: 10.1007/s00277-023-05572-0. Online ahead of print. Effectiveness of tixagevimab/cilgavimab in patients with hematological malignancies as a pre-exposure prophylaxis to prevent severe COVID-19: a Czech retrospective multicenter study
Ivo Demel[SUP] 1 2 [/SUP], David Skopal[SUP] 3 [/SUP], Eliška Šafránková[SUP] 3 [/SUP], Petra Rozsívalová[SUP] 4 5 [/SUP], Pavel Jindra[SUP] 6 [/SUP], Jiří Šrámek[SUP] 6 7 [/SUP], Adéla Turková[SUP] 6 [/SUP], Jan Vydra[SUP] 8 [/SUP], Klára Labská[SUP] 8 [/SUP], Jana Vedrová[SUP] 8 [/SUP], Martin Čerňan[SUP] 9 [/SUP], Tomáš Szotkowski[SUP] 9 [/SUP], Heidi Móciková[SUP] 10 [/SUP], Lenka Hynková[SUP] 10 [/SUP], Ondrej Šušol[SUP] 11 12 [/SUP], Ingrid Kováčová[SUP] 11 [/SUP], David Belada[SUP] 3 [/SUP], Roman Hájek[SUP] 11 12 [/SUP]
Affiliations
Despite lower virulence, the omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that causes coronavirus disease 2019 (COVID-19) still poses a relevant threat for immunocompromised patients. A retrospective multicentric study was conducted to evaluate the efficacy of pre-exposure prophylaxis with tixagevimab/cilgavimab (Evusheld) with a 6-month follow-up for preventing severe COVID-19 in adult patients with hematology malignancy. Among the 606 patients in the cohort, 96 (16%) contracted COVID-19 with a median of 98.5 days after Evusheld administration. A total of 75% of patients had asymptomatic or mild severity of COVID-19, while just 25% of patients with SARS-CoV-2 positivity had to be hospitalized. Two patients (2%) died directly, and one patient (1%) in association with COVID-19. Eight patients (1.3%) of every cohort experienced adverse events related to Evusheld, mostly grade 1 and of reversible character. It was found that complete vaccination status or positive seroconversion was not associated with lower risk of COVID-19 infection. Previous treatment with an anti-CD20 monoclonal antibody was associated with higher rates of COVID-19, while previous treatment with anti-CD38 monoclonal antibody was not, as was the case for recipients of hematopoietic stem cell transplantation or CAR-T cell therapy. Presence of other comorbidities was not associated with more severe COVID-19. The results support the growing evidence for Evusheld's efficacy against severe COVID-19 in patients with hematology malignancies.
Keywords: COVID-19; Hematology malignancy; SARS-CoV-2; Tixagevimab/cilgavimab.
. 2023 Dec 14.
doi: 10.1007/s00277-023-05572-0. Online ahead of print. Effectiveness of tixagevimab/cilgavimab in patients with hematological malignancies as a pre-exposure prophylaxis to prevent severe COVID-19: a Czech retrospective multicenter study
Ivo Demel[SUP] 1 2 [/SUP], David Skopal[SUP] 3 [/SUP], Eliška Šafránková[SUP] 3 [/SUP], Petra Rozsívalová[SUP] 4 5 [/SUP], Pavel Jindra[SUP] 6 [/SUP], Jiří Šrámek[SUP] 6 7 [/SUP], Adéla Turková[SUP] 6 [/SUP], Jan Vydra[SUP] 8 [/SUP], Klára Labská[SUP] 8 [/SUP], Jana Vedrová[SUP] 8 [/SUP], Martin Čerňan[SUP] 9 [/SUP], Tomáš Szotkowski[SUP] 9 [/SUP], Heidi Móciková[SUP] 10 [/SUP], Lenka Hynková[SUP] 10 [/SUP], Ondrej Šušol[SUP] 11 12 [/SUP], Ingrid Kováčová[SUP] 11 [/SUP], David Belada[SUP] 3 [/SUP], Roman Hájek[SUP] 11 12 [/SUP]
Affiliations
- PMID: 38092996
- DOI: 10.1007/s00277-023-05572-0
Despite lower virulence, the omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that causes coronavirus disease 2019 (COVID-19) still poses a relevant threat for immunocompromised patients. A retrospective multicentric study was conducted to evaluate the efficacy of pre-exposure prophylaxis with tixagevimab/cilgavimab (Evusheld) with a 6-month follow-up for preventing severe COVID-19 in adult patients with hematology malignancy. Among the 606 patients in the cohort, 96 (16%) contracted COVID-19 with a median of 98.5 days after Evusheld administration. A total of 75% of patients had asymptomatic or mild severity of COVID-19, while just 25% of patients with SARS-CoV-2 positivity had to be hospitalized. Two patients (2%) died directly, and one patient (1%) in association with COVID-19. Eight patients (1.3%) of every cohort experienced adverse events related to Evusheld, mostly grade 1 and of reversible character. It was found that complete vaccination status or positive seroconversion was not associated with lower risk of COVID-19 infection. Previous treatment with an anti-CD20 monoclonal antibody was associated with higher rates of COVID-19, while previous treatment with anti-CD38 monoclonal antibody was not, as was the case for recipients of hematopoietic stem cell transplantation or CAR-T cell therapy. Presence of other comorbidities was not associated with more severe COVID-19. The results support the growing evidence for Evusheld's efficacy against severe COVID-19 in patients with hematology malignancies.
Keywords: COVID-19; Hematology malignancy; SARS-CoV-2; Tixagevimab/cilgavimab.